US Patent

US8597272 — Pharmacokinetics of iontophoretic sumatriptan administration

Formulation · Assigned to NuPathe Inc · Expires 2027-04-12 · 1y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent describes improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan succinate.

USPTO Abstract

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

Patent Metadata

Patent number: US8597272
Jurisdiction: US
Classification: Formulation
Expires: 2027-04-12
Drug substance claim: No
Drug product claim: Yes
Assignee: NuPathe Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.